Showing 2311-2320 of 4063 results for "".
- Moderna’s Variant-Specific COVID-19 Vaccine Candidate Ready for Clinical Testinghttps://modernod.com/news/modernas-variant-specific-covid-19-vaccine-candidate-ready-for-clinical-testing/2478914/Moderna said that it has manufactured the initial batch of an updated version of its COVID-19 vaccine designed to better protect against the B.1.351 variant of SARS-CoV-2 first identified in South Africa. The company indicated late last month that it would be working on the variant-specific boost
- Pfizer’s COVID-19 Vaccine Stimulates Lower Antibody Response Against B.1.351 Strainhttps://modernod.com/news/pfizers-covid-19-vaccine-stimulates-lower-antibody-response-against-b-1-351-strain/2478888/Preliminary findings from an in vitro study published Wednesday in the NEJM showed that Pfizer and BioNTech’s COVID-19 vaccine BNT162b2 elicited roughly two-thirds lower levels of neutralizing antibodies against a highly transmissible SARS-CoV-2 variant that was first spotted in So
- Gyroscope Therapeutics Announces Positive Interim Data from Phase 1 FOCUS Trial of Investigational Gene Therapy GT005https://modernod.com/news/gyroscope-therapeutics-announces-positive-interim-data-from-phase-1-focus-trial-of-investigational-gene-therapy-gt005/2478865/Gyroscope Therapeutics announced positive interim safety, protein expression and biomarker data from the ongoing open-label phase 1/2 FOCUS clinical trial of its investigational gene therapy, GT005, in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Inte
- Palatin Technologies Announces Filing of International Patent Application for Lead Compound for Dry Eye Diseasehttps://modernod.com/news/palatin-technologies-announces-filing-of-international-patent-application-for-lead-compound-for-dry-eye-disease/2478853/Palatin Technologies announced the filing of an international patent application under the Patent Cooperation Treaty (PCT) directed to the composition of PL9643 and a related family of melanocortin agonist peptides. Palatin recently reported positive results in its phase 2 study of PL9643
- Lilly Teams Up With GSK, Vir to Test Antibody Combination Against COVID-19https://modernod.com/news/lilly-teams-up-with-gsk-vir-to-test-antibody-combination-against-covid-19/2478808/Eli Lilly is expanding the ongoing phase 2 BLAZE-4 trial to include testing a combination of its antibody treatment bamlanivimab with VIR-7831, a dual-action antibody being co-developed by GlaxoSmithKline and Vir Biotechnology, for use in low-risk patients with mild-to-moderate COVID-19, the comp
- Regeneron’s Antibody Cocktail Shows Promise as ‘Passive Vaccine’ Against COVID-19https://modernod.com/news/regenerons-antibody-cocktail-shows-promise-as-passive-vaccine-against-covid-19/2478804/Regeneron Pharmaceuticals reported initial results from a phase 3 study showing that, compared to placebo, its antibody cocktail REGEN-COV (casirivimab/imdevimab) reduced overall COVID-19 infections seen within the first week among people at high risk of contracting SARS-CoV-2, with 100% pr
- Lilly’s Bamlanivimab Cuts Risk of COVID-19 By Up to 80% at Nursing Homeshttps://modernod.com/news/lillys-bamlanivimab-cuts-risk-of-covid-19-by-up-to-80-at-nursing-homes/2478788/Eli Lilly announced Thursday that in a phase 3 study, bamlanivimab was shown to significantly reduce the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities. The findings from the BLAZE-2 COVID-19 prevention trial suggest the risk was decreased by up to
- New Data Back Ability of Pfizer, BioNTech’s COVID-19 Vaccine to Foil UK Strainhttps://modernod.com/news/new-data-back-ability-of-pfizer-biontechs-covid-19-vaccine-to-foil-uk-strain/2478782/Pfizer and BioNTech on Wednesday reported results from another in-vitro study indicating that their COVID-19 vaccine BNT162b2 is likely capable of neutralizing the rapidly spreading UK strain of SARS-CoV-2, also known as B.1.1.7. The findings, which were published on the preprint server bioRxiv,
- JPM: How did Pfizer Up its COVID-19 Vaccine Capacity? ‘Out of the Box Manufacturing,’ CEO Sayshttps://modernod.com/news/jpm-how-did-pfizer-up-its-covid-19-vaccine-capacity-out-of-the-box-manufacturing-ceo-says/2478757/Earlier this week, Pfizer partner BioNTech upped the pair’s 2021 COVID-19 output projection to 2 billion doses for 2021, up from a previous estimate of 1.3 billion. But how will the companies get there? By doing things “very differently and very out of the box in manufacturing,” CEO Albert Bourla
- ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10https://modernod.com/news/proqr-completes-enrollment-of-its-pivotal-trial-of-sepofarsen-for-the-treatment-of-lca10/2478728/ProQR Therapeutics announced it has completed patient enrollment in its phase 2/3 Illuminate study of sepofarsen for the treatment of Leber Congenital Amaurosis 10 (LCA10) due to the p.Cys998X mutation in the CEP290 gene. With enrollment completed, topline results are expected in the first half (